share_log

Chardan Capital Initiates Coverage On Century Therapeutics With Buy Rating, Announces Price Target of $19

Benzinga Real-time News ·  Dec 27, 2022 18:46

Chardan Capital analyst Geulah Livshits initiates coverage on Century Therapeutics (NASDAQ:IPSC) with a Buy rating and announces Price Target of $19.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment